VerdePharmHealth and Altopa Enter into Exclusive Partnership Agreement for Patient-Centric CBD Formulations
Summary
NEW HOPE, Pa.--(BUSINESS WIRE)--VerdePharmHealth today announced the signing of an exclusive national group purchasing agreement with Altopa, creator of the Oblend™, a patented device and technology platform that is able to create personalized, consistent products that leverage the new science around custom blended terpenes that are essential to maximizing patient outcomes. “There are a host of botanical extracts, including cannabinoids and terpenes, that work in concert to modulate how cannabis addresses targeted symptoms, a phenomenon known as the entourage effect. Both companies are working to provide accessibility, enhance outcomes, collect clinical evidence, standardize protocols, and move cannabis science forward. This is fully aligned with our approach to partnering with innovative and highly compliant manufacturers on behalf of our network and their patients.” The companies plan future collaborations focused on observational real-world evidence studies around plant based alternatives to opioids and other pharmaceuticals and their often devastating side effects. VerdePharmHealth, the first organization of its kind in the U.S., provides comprehensive multi-specialty group purchasing, clinical solutions, and healthcare technology designed to drive high-level commitment and affordability for members through accessibility of quality cannabis products from prequalified manufacturers and leveraging of clinical services and robust technology to improve decisions for interventions at the point of care and capture real-world evidence.